Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comparative Study
. 2023 Nov;16(11):2144-2152.
doi: 10.1111/cts.13603. Epub 2023 Aug 7.

Comparison of glutaminase and cancer antigen 125 for distinguishing benign and malignant ovarian tumors

Gatot Nyarumenteng Adhipurnawan Winarno  1 , Jusuf Sulaeman Effendi  1 , Ali Budi Harsono  1 , Siti Salima  1 , Bagja Dumas Darwizar  1 , R M Sonny Sasotya  1 , Anita Rachmawati  1 , Ayu Insafi Mulyantari  1 , Nurvita Trianasari  2 , Budi Handono  1
Affiliations
Comparative Study

Comparison of glutaminase and cancer antigen 125 for distinguishing benign and malignant ovarian tumors

Gatot Nyarumenteng Adhipurnawan Winarno et al. Clin Transl Sci. 2023 Nov.

Abstract

Increasing demand for glutaminase (GLS) due to high rates of glutamine metabolism is considered one of the hallmarks of malignancy. In parallel, cancer antigen 125 (CA-125) is a commonly used ovarian tumor marker. This study aimed to compare the roles of GLS and CA-125 in distinguishing between benign and malignant ovarian tumors. The research was conducted as a comparative study, enrolling 156 patients with ovarian tumors. Preoperative serum CA-125 and GLS levels were analyzed to evaluate their effectiveness in distinguishing between benign and malignant ovarian tumors. The results revealed that the mean levels of CA-125 and GLS were significantly higher in malignant ovarian tumors compared with benign ones (389.54 ± 494.320 vs. 193.15 ± 529.932 (U/mL) and 17.37 ± 12.156 vs. 7.48 ± 4.095 (μg/mL), respectively). The CA-125 and GLS cutoff points of 108.2 U/mL and 18.32 μg/mL, respectively, were associated with malignant ovarian tumors. Multivariate analyses showed that GLS had higher predictive capabilities compared with CA-125 (odds ratio 9.4 vs. 2.1). The accuracy of using GLS combined with CA-125 was higher than using CA-125 alone (73.1% vs. 68.8%). In conclusion, higher levels of CA-125 and GLS are associated with malignant ovarian tumors. GLS outperforms CA-125 in distinguishing between benign and malignant ovarian tumors. The combination of GLS and CA-125 demonstrated improved accuracy for distinguishing benign and malignant ovarian tumors when compared with using CA-125 alone.

PubMed Disclaimer

Conflict of interest statement

The authors have declared no competing interests in this work.

Figures

FIGURE 1
FIGURE 1
Distribution of glutaminase (GLS) values in ovarian tumor patients.
FIGURE 2
FIGURE 2
Distribution of cancer antigen 125 (CA‐125) values in ovarian tumor patients.
FIGURE 3
FIGURE 3
Correlation of glutaminase (GLS) and cancer antigen 125 (CA‐125) serum in ovarian tumor patients.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Cancer Today ‐ Global Cancer Observatory . Estimated number of incident cases and deaths world, females, all ages. 2023. Accessed January 10, 2023. https://gco.iarc.fr/today/data/factsheets/populations/900‐world‐fact‐she...
    1. ACOG Committee Opinion No. 754 . The utility of and indications for routine pelvic examination. Obstet Gynecol. 2018;132(4):e174‐e180. - PubMed
    1. Van Nagell J, Hoff J. Transvaginal ultrasonography in ovarian cancer screening: current perspectives. Int J Womens Health. 2013;6:25‐33. - PMC - PubMed
    1. Scholler N, Urban N. CA‐125 in ovarian cancer. Biomark Med. 2007;1(4):513‐523. - PMC - PubMed
    1. Donach M, Yu Y, Artioli G, et al. Combined use of biomarkers for detection of ovarian cancer in high‐risk women. Tumor Biol. 2010;31(3):209‐215. - PubMed

Publication types